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ABSTRACT  
Objective: Mendelian Randomization (MR) is a technique that aims to assess causal effects 
of exposures on disease outcomes. The aim of this paper is to present the main assumptions 
that underlie MR, the statistical methods used to estimate causal effects and how to account 
for potential violations of the key assumptions.  
Methods: We discuss the key assumptions that should be satisfied in an MR setting. We list 
the statistical methodologies used in two-sample MR when summary data are available to 
estimate causal effects (i.e. Wald Ratio estimator, Inverse-Variance Weighted and Maximum 
likelihood method) and identify/ adjust for potential violations of MR assumptions (i.e. MR-
Egger regression and Weighted Median approach). We also present statistical methods and 
graphical tools used to evaluate the presence of heterogeneity. 
Results: We use as an illustrative example a published two-sample MR study, investigating 
the causal association of body mass index with three psychiatric disorders (i.e. bipolar 
disorder, schizophrenia and major depressive disorder). We highlight the importance of 
assessing the results of all available methods rather than each method alone. We also 
demonstrate the impact of heterogeneity in the estimation of the causal effects.  
Conclusions: MR is a useful tool to assess causality of risk factors in medical research. 
Assessment of the key assumptions underlying MR is crucial for a valid interpretation of the 
results.  
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INTRODUCTION 
Mendelian Randomization (MR) is a technique that aims to investigate if an exposure is 
causally contributing to a disease outcome using genetic variants as proxies for environmental 
exposures 1 . The reason for utilizing MR is to overcome many drawbacks of observational 
epidemiology, such as confounding and reverse causation. MR is analogous to a randomized 
control trial (RCT) where instead of the allocation of participants to different treatment 
groups,  individuals are randomized by nature to carry or not carry genetic variants that may 
modify the risk of an exposure 1.  
An MR analysis is feasible using either individual-level data (one-sample) or summary 
data (two-sample), where the association of genetic variant(s) with the exposure and the 
outcome are available. For one-sample MR, the association of genetic variant(s) with the 
exposure and genetic variant(s) with the outcome are estimated in the same sample, while in 
the latter in different non-overlapping samples 2. For two-sample MR, the increasing 
availability and scale of summary data from genome-wide association studies (GWAS) are 
used to estimate the causal effect of the exposure on an outcome. By using such summary 
statistics, one can avoid additional complications arising from confidentiality agreements, 
especially when it comes to large consortia. Additionally, collaborative efforts from large 
GWAS have identified numerous genetic variants, explaining a high proportion of the 
heritability of the tested phenotypes and can be used to derive accurate and precise causal 
effects 3.  
The aim of this review is to provide an overview of two-sample MR when summary data 
are available, its assumptions and estimation methods. We include an illustrative example of 
medical relevance with a focus on the field of mental health. 
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METHODS 
MR assumptions 
The instrumental variable method, initially introduced in econometrics and social 
sciences, is an approach to account for confounding and thus infer causality in observational 
settings 4 5. An instrumental variable is selected as to mimic the randomization of individuals 
to the exposure ensuring compatibility of groups with respect to any measured or unmeasured 
confounders. An MR uses genetic variants associated with an exposure as instruments to infer 
causality on an outcome. For a genetic variant to be a valid instrument, three assumptions 
must be satisfied, (i) the genetic variant (G) must be strongly associated with the exposure of 
interest X, (ii) the genetic variant is not associated with any confounder (U) of the exposure-
outcome association (iii) the genetic variant is only associated with the outcome (Y) through 
the exposure (Figure 1) 4. 
 The first assumption is the only assumption that can be formally tested and in 
practice genetic variants that are related to a given exposure at the genome-wide significance 
level are used as instruments (p-value<5×10-8). The second and third assumptions can be 
assessed by estimating the associations between the genetic variants and a large set of 
confounders. However, when summarized data are available (i.e. two-sample MR) assessing 
the associations between the genetic variants and confounders, is based solely on literature 
evidence, which could be not measured/reported6. Overall, there is no way to prove that the 
second and third MR assumptions definitively hold. However, it is often possible to find 
empirical evidence suggesting that the instruments under consideration are invalid. In 
practice, we can indirectly evaluate MR assumptions by checking if there is high 
reproducibility of the MR causal estimates in different studies and if all available MR 
estimation methods yield concordant results. 
Selection of instruments 
 Genetic variants for gene-exposure associations can be obtained either by extensive 
catalogues of published GWAS, such as GWAS Catalog and MR-BASE7 8, or publicly 
available data of genetic consortia. Table 1 contains a list of genetic consortia for mental 
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health disorders. Genetic variants must be strongly associated with the exposure at a genome-
wide significance level (p-value<5×10-8). Genetic variants are then pruned and independent 
variants (not in linkage disequilibrium [LD] which is the non-random association of alleles at 
two or more loci in a general population) are taken forward for analysis. However, methods 
accounting for the correlation structure have been also proposed and can be used to increase 
statistical power when only a few variants for the exposure of interest are available and these 
explain a low proportion of the variability9. 
 
Table 1: Genetic consortia with publicly available data for psychiatric disorders. 
 
Genetic consortium Disease under study 
 
Psychiatric Genomics Consortium (PGC) 
 
Anorexia, Autism, Bipolar Disorder, 
Schizophrenia, Obsessive Compulsive 
Disorder (OCD), Post-Traumatic Stress 
Disorder (PTSD), Attention 
Deficit/Hyperactivity Disorder (ADHD) 
 
 
CommonMind Consortium 
 
 
Bipolar disorder, Schizophrenia 
 
International Genomics of Alzheimer’s 
Project (IGAP) 
 
 
Alzheimer’s disease 
  
 
Estimation methods 
MR estimation methods can be broadly grouped into two main categories depending on 
the number of the available instruments: (i) when a single variant is available (Wald Ratio 
estimator) and (ii) when multiple variants are available (Inverse Variance Weighted method 
[IVW] and Maximum Likelihood method [ML]).  
a) Wald Ratio estimator 
When a single genetic variant is available, the easiest method for calculating the 
causal effect of an exposure on an outcome is the Wald Ratio. This can be considered 
as the change in the outcome resulting from a unit change in the exposure and can be 
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calculated by the ratio of the regression coefficient of the gene-outcome association 
to the regression coefficient of the gene-exposure association10. Thus, if we denote by 
ˆ
X  and 
ˆ
Y the estimated regression coefficients of the exposure and the outcome, 
respectively, on the genetic variant, then the ratio estimate can be expressed as: 
ˆ
ˆ
ˆ
Y
MR
X



=  
A standard error can be approximately estimated using the Delta method11. 
b) Inverse Variance Weighted method (IVW) 
When multiple genetic variants are associated with the exposure of interest the Wald 
ratio method can be extended by borrowing methodology from the field of meta-
analysis. In particular, the ratio estimates of the causal effects from each genetic 
variant are combined employing an Inverse Variance Weighted (IVW) meta-analysis 
framework. Thus, the IVW method is a weighted average of the causal effects derived 
from the genetic variants. This method is equivalent to fitting a weighted linear 
regression of the associations of the instruments with the outcome on the instruments 
with the exposure setting the intercept term to zero. Notably, this method assumes 
that all instruments are valid and no pleiotropic effects exist (i.e. the genetic variants 
are not associated with multiple exposures). Thus, differences in the causal estimates 
as estimated by each genetic variant individually are due to sampling variability 
(homogeneity assumption)6 9 12. 
c) Maximum Likelihood method (ML) 
Assuming that outcome and exposure are linearly dependent and jointly normally 
distributed the causal effect of exposure on outcome can be estimated by direct 
maximization of the likelihood, allowing for uncertainty in both exposure and 
outcome6 9. 
When gene-exposure associations are precisely estimated, then IVW and ML method give 
similar results. However, when considerable imprecision exists, IVW produces over-precise 
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causal estimates, while ML results in wider and therefore appropriately-sized confidence 
intervals (CIs), as ML allows for uncertainty in both gene-exposure and gene-outcome 
associations9. 
Accounting for violation of MR assumptions 
When all genetic variants satisfy the assumptions of an MR study, causal effect estimates 
derived from IVW and ML are unbiased. There are several methods that have been developed 
to identify, allow and correct for violations of assumptions, when some of the selected 
variants are invalid instruments. 
a) MR-Egger  
In the presence of pleiotropy, one could fit a weighted linear regression of the 
associations of the instruments with the outcome on the instruments with the 
exposure, while assuming an unconstrained intercept term (unlike the IVW approach 
where intercept term is constrained and set to zero), resulting in the so-called MR-
Egger regression method13 14. The slope of the MR-Egger regression is a robust 
estimate of the causal effect accounting for potential horizontal pleiotropy (i.e. when 
the genetic variant(s) has an effect on the outcome, independently of the exposure 
under study). MR-Egger requires that gene-exposure and gene-outcome associations 
are independent (Instrument Strength Independent on Direct Effect-InSIDE 
assumption) and that the variance of the association of the genetic variants with the 
exposure association is negligible (No Measurement Error-NOME assumption). 
However, the MR-Egger approach can be underpowered when few instruments are 
available. 
b) Weighted Median estimator   
When up to 50% of genetic variants are invalid instruments, then a causal effect can 
be estimated as the median of the weighted ratio estimates using as weights the 
reciprocal of variance of the ratio estimate15. The InSIDE assumption is not 
necessary. Violations of the second and the third assumptions are also allowed. 
c)  Heterogeneity as an indication of pleiotropy 
 9 
 
In an MR setting we assume that all the instruments estimate the same underlying 
causal effect and any discrepancies are an indication of pleiotropy. It is likely that the 
pleiotropic effects of individual genetic variants cancel each other out, as they could 
be either positive or negative. However, when substantial heterogeneity is present the 
estimated causal effect will be imprecisely estimated. This heterogeneity can be 
quantified using the Cochran’s Q statistic or the I2 metric. A scatter plot with gene-
outcome against gene-exposure associations provides a visual inspection of 
pleiotropy. Under the hypothesis of no heterogeneity, all plotted points must be 
compatible with a line passing through the origin. One could also plot the precision of 
the instruments  against MR causal estimates and any asymmetry is an indication of 
potential pleiotropic effects 16. 
d) Leave one out analysis  
As already discussed, IVW and MR-Egger methods are formulated as a regression of 
the gene-outcome associations on gene-exposure associations with an intercept term to 
be constrained or not to zero respectively. As in any regression model, outlying data 
points could bias the estimated causal effect. Therefore, the influence of each variant 
can be assessed by re-estimating the causal association after excluding one genetic 
variant at a time and any deviances may serve as an indication of potential pleiotropic 
effects14. 
RESULTS 
Illustrative example  
Hartwig and colleagues conducted a two-sample MR study to investigate the potential 
causal associations of body-mass index (BMI) with three psychiatric disorders (bipolar 
disorder, schizophrenia and major depressive disorder)17.  
Publicly available genetic data for BMI were retrieved from the Genetic Investigation 
of Anthropometric Traits (GIANT) consortium for 322,154 European ancestry individuals18. 
Corresponding genetic variants for the three psychiatric disorders were extracted from the 
Psychiatric Genomics Consortium (PCG) (http://www.med.unc.edu/pgc/downloads). This 
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included summary association data for a total of 7,481 bipolar disorder cases/ 9,250 controls; 
34,241 schizophrenia cases/45,604 ancestry matched controls; and 9,240 major depressive 
disorder cases/9,519 controls19-21. In total, 97 genetic variants-single-nucleotide 
polymorphisms (SNPs) were identified at a genome-wide significance level (p-value<510-8) 
for BMI. For schizophrenia, one SNP (i.e. rs12016871) was not available. For major 
depressive disorder, 90 SNPs were extracted (for 28 out of these 90 SNPs proxies were 
chosen using the 1000 Genomes Pilot 1 and HapMap release 22 as reference panels). 
 The SNP-BMI associations were calculated applying an inverse-normal 
transformation on BMI measurements and the MR estimates corresponded to 1-standard 
deviation (SD) increase in BMI. For bipolar disorder and schizophrenia, IVW and ML 
methods yielded identical non-significant MR estimates (bipolar disorder odds ratio [OR]: 
0.90; 95% CI: 0.69-1.16 and schizophrenia OR: 0.98; 95% CI: 0.80-1.19). There was no 
evidence for an association of BMI with bipolar disorder and schizophrenia when using the 
weighted median approach (bipolar disorder OR: 0.88, 95% CI: 0.62-1.25; and schizophrenia 
OR: 0.93, 95% CI: 0.78-1.11). Notably, the MR-Egger approach yielded directionally 
inconsistent estimates with an OR equal to 1.23 (95% CI: 0.65-2.31) for bipolar disorder and 
an OR equal to 1.41 (95% CI: 0.87-2.27) for schizophrenia. All methods showed little 
evidence for association with consistent direction for the association of BMI with major 
depressive disorder with some evidence of association from the weighted median approach 
(OR: 1.40; 95% CI: 1.03-1.90) (Figure 2). For all psychiatric disorders, the MR-Egger 
intercept was approximately equal to 1.00 indicating no violation of the MR assumptions due 
to pleiotropic effects (bipolar disorder OR: 0.99; 95% CI: 0.97-1.01, schizophrenia OR: 0.99; 
95% CI: 0.98-1.00, MD OR: 1.00; 95% CI: 0.98-1.01). Substantial heterogeneity was 
quantified by the Q-statistics for all tested outcomes (Figure 2). As shown in Figure 3, there 
were some SNPs that could be considered outliers and potentially increase statistical 
heterogeneity. Removing outlying variants resulted in nearly identical results for bipolar 
disorder. For schizophrenia, the MR estimates did not change for all methods with the 
exception of the MR-Egger approach, where a weaker causal association with increased 
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precision was observed (OR: 1.22; 95% CI: 0.83-1.81). Excluding possible pleiotropic 
variants in major depressive disorder, all methods yielded comparable results in direction with 
some evidence of association derived by the IVW method (OR: 1.25; 95% CI: 1.02-1.52). 
Conclusively, only for major depressive disorder the results of all methods were 
concordant and the association was even stronger after removing influential SNPs. Therefore, 
one can conclude that there might be a true causal effect of BMI on major depressive disorder 
although the statistical evidence was weak. In contrast, the discrepancy between methods in 
bipolar disorder and schizophrenia, does not allow for any safe conclusions. Thus, the 
reported association of BMI with psychiatric disorders in observational studies may have 
been confounded22-24.   
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DISCUSSION 
 MR aims to identify and quantify potential causal associations between exposures and 
outcomes of major health importance. Mostly due to the substantial increment of information 
available by genetic studies, relating the genetic architecture of various phenotypes and 
diseases, its popularity has increased. Implementing statistical methods borrowed from the 
field of meta-analysis, to synthesize summary effects of multiple genetic variants to estimate 
causal effects, has increased its feasibility. As a result, even researchers with non-statistical 
backgrounds can implement a MR study effectively, by using software such as the MR-Base 
for this purpose 8. However, it is crucial that one keeps in mind the assumptions upon which 
the validity of estimated causal effect relies, especially when using summary-level data. 
 As discussed in this article, methods exist to assesses and adjust for different degrees 
of violation of the key assumptions. Both weighted median and MR-Egger can be used to 
estimate the causal effect of exposure on outcome, making different assumptions about the 
degree of violation of the MR assumptions. MR-Egger estimates robust causal effects of the 
exposure on the outcome, even if all genetic variants are invalid instruments. In contrast, 
weighted median requires at least half of them to be valid. Additionally, weighted median 
allows violation of the MR assumptions in a more general framework, while MR-Egger 
relaxes second and third assumptions by replacing them with weaker but still untestable 
assumptions (InSIDE and NOME assumptions)13. Generally, it is recommended to critically 
appraise all methods together. If the various methods yield results of similar magnitude, then 
it is more plausible that the produced results are reliable. On the other hand, if estimated 
causal effects are contradictory further evaluation should be considered and the results should 
be interpreted with caution.  
 In the era of -omics, Mendelian randomization is considered a powerful and 
promising technique, as it could utilize metabolomic, proteomic, and DNA methylation data, 
to better explain the contribution of certain metabolic pathways and gene regulations in the 
development of diseases25. Therefore, it is crucial for researchers to recognize that MR is a 
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method that requires statistical and biological knowledge, to make inferences that reflect more 
reliably the nature of complex diseases. 
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FIGURE LEGENDS 
Figure 1: Directed acyclic graph of Mendelian Randomization representing the assumptions (i) the genetic variant (G) 
must be associated with the exposure X, (ii) must not be associated with any confounder (U) of the exposure-outcome 
association and (iii) must be associated with the outcome (Y) only via the exposure. 
Figure 2: Mendelian randomization results of body mass index with psychiatric disorders. All estimates are reported 
per 1-standard deviation (SD) increase of body mass index. The data used in this example are obtained from a 
published study of Hartwig and coworkers17. 
Abbreviations: Odds ratio: OR, 95% confidence intervals: 95% CIs, Inverse Variance Weighted: IVW, Maximum 
Likelihood (ML), body mass index (BMI), single nucleotide polymorphisms (SNPs), Cohrans's Q P-value (P-het)  
Figure 3: Scatter plots of associations of the selected variants with (a) bipolar disorder (b) schizophrenia and (c) 
major depressive disorder and body mass index. The data used in this example are obtained from a published study of 
Hartwig and coworkers17. 
Abbreviations: body mass index (BMI), standard deviation (SD), natural logarithm of Odds Ratio (logOR)
 15 
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